GDRX NASDAQ
GoodRx Holdings, Inc.
1W: -1.1%
1M: +5.1%
3M: +8.1%
YTD: +26.6%
1Y: -11.9%
3Y: -36.6%
5Y: -92.2%
$3.48
-0.08 (-2.25%)
Weekly Expected Move ±5.3%
$3
$3
$4
$4
$4
Credit Risk of going bust: higher than 67% of companies Debt: 31.2% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.15 (down 96%), GoodRx Holdings, Inc. would be worth roughly what it owes.
Total debt $539.0M against a stock market value of $1.19B.
Distance to default 3.62 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $245.8M (short-term plus half of long-term), stock volatility 55.9%; Altman Z'' -0.08. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.15 (down 96%), GoodRx Holdings, Inc. would be worth roughly what it owes.
Total debt $539.0M against a stock market value of $1.19B.
Distance to default 3.62 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $245.8M (short-term plus half of long-term), stock volatility 55.9%; Altman Z'' -0.08. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
19 relationships17
As Filer
counterparties named
2
As Counterparty
mentioned by others
3
Rel. Types
2022-03-07
Earliest Filing
2024-02-26
Latest Filing
partner: 12
target: 4
customer: 1
Counterparties (Filed by GDRX)
17 relationshipsCompanies named in GDRX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| GoodRx, Inc. | GRDX | customer | Primary borrower in the credit agreement amendment | 2024-02-26 | View |
| GoodRx Intermediate Holdings, LLC | GDRX | partner | Guarantor and holding company for the credit agreement | 2024-02-26 | View |
| GoodRx, Care, LLC | GDRX | partner | Guarantor for the credit agreement | 2024-02-26 | View |
| ScriptCycle, LLC | — | partner | Guarantor for the credit agreement | 2024-02-26 | View |
| Healthination Inc. | — | partner | Guarantor for the credit agreement | 2024-02-26 | View |
| RxSaver, Inc. | — | partner | Guarantor for the credit agreement | 2024-02-26 | View |
| Buckeye Acquisition, LLC | — | partner | Guarantor for the credit agreement | 2024-02-26 | View |
| FlipMD, Inc. | — | partner | Guarantor for the credit agreement | 2024-02-26 | View |
| Pharmacy Services, LLC | — | partner | Guarantor for the credit agreement | 2024-02-26 | View |
| GoodRx Care, LLC | GDRX | partner | Guarantor for the credit agreement | 2024-02-26 | View |
| Iodine, Inc. | — | partner | Guarantor for the credit agreement | 2024-02-26 | View |
| Lighthouse Acquisition Corp. | — | partner | Guarantor for the credit agreement | 2024-02-26 | View |
| Vitacare Prescription Services, Inc. | — | partner | Guarantor for the credit agreement | 2024-02-26 | View |
| vitaCare Prescription Services, Inc. | — | target | Target company acquired by GoodRx Holdings, Inc. | 2022-04-15 | View |
| TherapeuticsMD, Inc. | TXMD | target | Sole stockholder of vitaCare and seller of the acquired assets. | 2022-04-15 | View |
| vitaCare Prescription Services, Inc. | — | target | Target company acquired by GoodRx Holdings, Inc. | 2022-03-07 | View |
| TherapeuticsMD, Inc. | TXMD | target | Sole stockholder of vitaCare and seller of the acquired business. | 2022-03-07 | View |
Mentioned As Counterparty
2 mentionsOther companies that named GDRX in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| TXMD TherapeuticsMD, Inc. | target | Acquired vitaCare Prescription Services, Inc. from TherapeuticsMD, Inc. for approximately $150 million in cash. | 2022-04-20 | View |
| TXMD TherapeuticsMD, Inc. | target | Acquired vitaCare Prescription Services, Inc. from TherapeuticsMD, Inc. | 2022-03-10 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-05 | Officer/Director Change | View | |
| 2026-08-05 | Earnings Release; Exhibits | View | |
| 2026-06-18 | Shareholder Vote | View | |
| 2026-05-06 | Earnings Release; Exhibits | View | |
| 2026-04-24 | Officer/Director Change | View | |
| 2026-04-03 | Officer/Director Change | View | |
| 2026-03-27 | Officer/Director Change | View | |
| 2026-03-18 | Accountant Change; Exhibits | View | |
| 2026-03-06 | Departure/Election of Directors; Appointment of Officers | View | |
| 2026-02-27 | Departure/Election of Directors; Appointment of Officers | View | |
| 2026-02-25 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-12-12 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-11-04 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-03 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-08-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-04 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-17 | Other Events | View | |
| 2025-02-27 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-02-05 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR